Mikozis Fungoides Tedavisinde Topikal Retinoidler
Özet
Retinoidler, biyolojik etkilerini retinoik asitlere duyarlı nükleer reseptörlere bağlanarak modüle ederler. Oluşan reseptör-ligand kompleksleri hücre diferansiyasyonu, proliferasyonu ve apopitozisini kontrol eden genlerin modülasyonunu sağlayan transkripsiyon faktörleri gibi fonksiyon gösterir. Kutanöz T hücreli lenfomada (KTHL) topikal retinoidler immunsüpresyona neden olmadan biyolojik yanıt düzenleyici görevleri ile iyi bir tedavi seçeneği olarak dikkat çekicidir. KTHL tedavisinde yer alan başlıca retinoidler beksaroten, tazaroten ve alitretinoindir. Bununla birlikte sadece topikal beksaroten erken evre tedavilere dirençli KTHL hastalarında FDA onayı almış ve tedavi rehberlerinde yer bulmuştur. Bu bölümde KTHL tedavisinde kullanılan topikal retinoidlerden beksaroten, tazaroten ve alitretinoinden bahsedilecektir.
Referanslar
Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53(3):358-88.
Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol. 1992;3(7):513-26.
Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10(9):940-54.
Ivanova D, Gaudon C, Rossin A, Bourguet W, Gronemeyer H. RAR-RXR selectivity and biological activity of new retinoic acid analogues with heterocyclic or polycyclic aromatic systems. Bioorg Med Chem. 2002;10(7):2099-102.
Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature. 1987;330(6147):444-50.
Hanley K, Jiang Y, He SS, Friedman M, Elias PM, Bikle DD, et al. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J Invest Dermatol. 1998;110(4):368-75.
Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164(3):1364-71.
Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett. 1991;57(3):223-7.
Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood. 2002;100(4):1399-403.
Cheng AL, Chuang SE, Su IJ. Factors associated with the therapeutic efficacy of retinoic acids on malignant lymphomas. J Formos Med Assoc. 1997;96(7):525-34.
Fujimura S, Suzumiya J, Anzai K, Ohkubo K, Hata T, Yamada Y, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res. 1998;22(7):611-8.
Meunier L, Bohjanen K, Voorhees JJ, Cooper KD. Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation. J Invest Dermatol. 1994;103(6):775-9.
Fox FE, Kubin M, Cassin M, Niu Z, Trinchieri G, Cooper KD, et al. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res. 1999;19(4):407-15.
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Group EGW. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi149-54.
Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem. 2000;275(7):4541-4.
Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, et al. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol. 2000;115(3):353-60.
Cheng SX, Kupper T. A new rexinoid for cutaneous t-cell lymphoma. Arch Dermatol. 2001;137(5):649-52.
Nawa T, Nawa MT, Cai Y, Zhang C, Uchimura I, Narumi S, et al. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun. 2000;275(2):406-11.
Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164(12):6503-8.
Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325-32.
Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801-15.
Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4):322-30.
Heyl J, Mehregan D, Kado J, Campbell M. A case of idiopathic follicular mucinosis treated with bexarotene gel. Int J Dermatol. 2014;53(7):838-41
Ledet J, Groysman V, Sami N. Woringer-Kolopp (Pagetoid Reticulosis) disease successful response to bexarotene gel. Dermatol Ther. 2016;29(1):28-31
Walling HW, Swick BL, Gerami P, Scupham RK. Folliculotropic mycosis fungoides responding to bexarotene gel. J Drugs Dermatol. 2008;7(2):169-71.
Ramachandran V, Park KE, Duvic M. Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later. Int J Dermatol. 2019;58(11):e221-e2.
Deonizio JM, Vaghani SP, Guitart J. Topical bexarotene for psoralen plus ultraviolet A-induced photodamage. J Am Acad Dermatol. 2013;69(2):e96-8.
Yazganoglu KD, Topkarci Z, Buyukbabani N, Baykal C. Childhood mycosis fungoides: a report of 20 cases from Turkey. J Eur Acad Dermatol Venereol. 2013;27(3):295-300.
Kalay Yildizhan I, Sanli H, Akay BN, Surgun E, Heper A. CD8(+) cytotoxic mycosis fungoides: a retrospective analysis of clinical features and follow-up results of 29 patients. Int J Dermatol. 2020;59(1):127-33.
Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004;50(4):600-7.
Besner Morin C, Roberge D, Turchin I, Petrogiannis-Haliotis T, Popradi G, Pehr K. Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma. J Cutan Med Surg. 2016;20(3):244-8.
Boehm MF, McClurg MR, Pathirana C, Mangelsdorf D, White SK, Hebert J, et al. Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties. J Med Chem. 1994;37(3):408-14.
Bubna AK. Alitretinoin in Dermatology-An Update. Indian J Dermatol.2015;60(5):520.
Bassiri-Tehrani S, Ba BA, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol. 2002;41(2):104-6.
